🔥 Trending Hims & Hers Stock Surges as FDA Panel Endorses Peptide BPC-157

Hims & Hers Health, Inc. (HIMS) is a health and wellness platform that aims to help individuals improve their well-being ¹. While Hims & Hers is a public company whose stock can be traded ⁴, the term "Hims & Hers' BPC-157 stock" is a bit misleading. BPC-157 is a peptide, not a stock owned by Hims & Hers in the traditional sense of company shares. Instead, the question likely refers to how the FDA's decision regarding BPC-157 might impact Hims & Hers' business operations, particularly if they offer or plan to offer products containing this peptide.

Understanding BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic peptide that has gained popularity for its purported benefits, including speeding up muscle recovery and improving sleep ². It is often marketed for its ability to heal injuries ⁹.

FDA Panel's Decision on BPC-157

On July 23, 2026, a panel of advisors to the U.S. Food and Drug Administration (FDA) voted to place BPC-157 on a list that would allow for broader pharmacy compounding ⁸. This decision is significant because the FDA had previously issued warnings about the risks associated with injecting peptides like BPC-157 ¹⁰.

It's important to note that this panel's decision does not constitute full FDA approval of BPC-157 ⁹. Instead, it moves BPC-157 towards a regulatory pathway that could make it more widely available to Americans through compounding pharmacies ²⁸. Compounding pharmacies create customized medications for individual patients, often when a commercially available drug doesn't meet specific needs.

Implications for Hims & Hers

The FDA panel's vote could have significant implications for companies like Hims & Hers. If BPC-157 becomes more broadly available through compounding, it could open new avenues for health and wellness platforms to offer products containing this peptide, subject to specific regulations and medical oversight. Hims & Hers, as a platform focused on health and wellness, may consider integrating such peptides into their offerings if the regulatory environment permits and aligns with their business model ¹.

While the exact impact on Hims & Hers' stock (HIMS) is subject to market dynamics and the company's strategic decisions, increased availability of popular peptides like BPC-157 could represent a potential growth area for health-focused companies. Investors often monitor regulatory developments for their potential effects on pharmaceutical and health-tech sectors ⁵⁶. As of July 23, 2026, Hims & Hers stock was originally listed at $10.13 in July 2019, with a significant return over the past seven years ⁷. Future stock performance will depend on various factors, including how the company adapts to evolving regulatory landscapes and market demands ³.